Artemetrx GeneCQ provides powerful, unique algorithms for one-time, curative, non-oncology gene therapies currently available on the market, as well as those expected to be available in the next year. We have strengthened this analysis by incorporating actuarial modeling techniques to provide the most comprehensive picture of potential costs and the associated timing.

Built on the Artemetrx pharmacy and medical claims integrated dataset, GeneCQ analyzes clinical history, demographics, diagnoses, and medication use. It calibrates a member-level risk score based on data and market insights related to ideal patient characteristics and uptake.

GeneCQ algorithms utilize actuarial models based on clinical and demographic attributes to quantify additional cost exposure not apparent within retrospective claims. This analysis is designed to account for instances of new member risk associated with births and new members added to the plan.

This tool provides users with an analysis by therapy and condition of potential drug administrations within a given policy period and the anticipated exposure.

Analyze the financial exposure within a policy period at both macro levels (e.g., book of business, LOB) as well as at an individual group level such as ASO.

Assess the anticipated PMPM cost within population. View member-level risk scores with drill down to the Integrated Member Profile.

A comprehensive view of the patient inclusive of medication, diagnosis, encounter, and provider history. Review high-risk patients to identify ways to improve care management.

View anticipated PMPM exposure for self-funded employer groups and model impact to stop loss rates.

© Pharmaceutical Strategies Group, LLC